Modelling Zika Virus Infection of the Developing Human Brain In Vitro Using Stem Cell Derived Cerebral Organoids
September 19th, 2017
12.6K views
This protocol describes a technique used to model Zika virus infection of the developing human brain. Using wildtype or engineered stem cell lines, researchers may use this technique to uncover the various mechanisms or treatments that may affect early brain infection and resulting microcephaly in Zika virus-infected embryos.
Overview
This study presents a protocol to model Zika virus infection in the developing human brain utilizing stem cell-derived organoids. Researchers aim to investigate which cells are susceptible to infection and the proteins involved in the infection pathway, providing insights into mechanisms of Zika virus infection and its link to microcephaly.
Key Study Components
Area of Science
- Neuroscience
- Virology
- Stem Cell Biology
Background
- Zika virus can lead to severe neurological disorders such as microcephaly in infected embryos.
- Understanding the infection mechanisms is crucial for developing therapeutic interventions.
- Stem cell-derived cerebral organoids serve as an effective model for early human brain development.
- This study explores the advantages of high throughput assays and genetic techniques like CRISPR.
Purpose of Study
- To model Zika virus infection in the developing human brain.
- To identify infected cell types and explore the infection pathway.
- To develop a platform for drug screening and understanding neurological impacts.
Methods Used
- The study employs stem cell-derived cerebral organoids as the primary platform.
- Stem cell lines are manipulated to produce organoids for infection studies.
- No multiomics workflows are mentioned; focus is on cellular infection dynamics.
- Key steps involve preparing organoid cultures, maintaining growth, and introducing viral infection.
- Regular medium changes are performed to ensure optimal growth conditions throughout the experimental timeline.
Main Results
- The protocol allows for observation of Zika virus infection mechanisms in organoids.
- Initial assessments highlight cell infection pathways and response mechanisms.
- Insights into cell differentiation and vulnerability to viral factors are gained.
- The study provides foundational insights for future therapeutic evaluations against Zika virus.
Conclusions
- This study enables detailed exploration of Zika virus impact on developing brains.
- Understanding of infection mechanisms may inform future therapeutic strategies to combat viral effects on brain development.
- Implications extend to broader investigations into neurodevelopmental disease models.
Frequently Asked Questions
What are the advantages of using stem cell-derived organoids?
Stem cell-derived organoids closely mimic human brain development and enable the study of virus interactions in a controlled environment, enhancing the relevance of findings.
How is Zika virus infection implemented in the organoid model?
Zika virus is introduced to the organoids after they have reached a specific growth stage, allowing researchers to study the infection process and its effects on brain development.
What types of data can be obtained from this study?
Researchers can gather data on cell viability, infection rates, and changes in molecular markers associated with Zika virus infection.
How can this method be adapted for drug screening?
The organoid model can be utilized to assess the efficacy of potential antiviral drugs that target Zika virus pathways by monitoring protective effects against infection.
What are some limitations of this study?
Limitations may include the complexity of mimicking the entire human brain environment and the potential variability in organoid responses to infection.
What implications does this study have for neuroscience?
This research enhances the understanding of viral impacts on brain development and could lead to improved therapeutic approaches for neurodevelopmental disorders.
Executive Industry Relevance
Modeling Zika virus infection in human cerebral organoids provides a species-matched system to evaluate neurotropic mechanisms and assess antiviral interventions. This approach supports target validation by identifying susceptible neural progenitor cells and infection pathways relevant to neurodevelopmental risk. The model enables mechanistic de-risking in early discovery by linking viral exposure to phenotypic outcomes such as cell death and microcephaly-like phenotypes.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Identifies neural progenitor cells as primary targets of Zika virus infection, supporting hypothesis testing of viral tropism.
- Operational Value: Enables interrogation of infection mechanisms using stem cell-derived systems that reflect human-specific biology.
- Strategic Value: Supports target confidence by clarifying which cell types and proteins are involved in the infection pathway.
Screening & Assay Development
- Scientific Value: Provides a three-dimensional platform for quantifying viral load and cytopathic effects over time.
- Operational Value: Compatible with high-throughput formats and genetic perturbation tools like CRISPR for pathway interrogation.
- Strategic Value: Enables scalable screening of compounds that modulate viral entry, replication, or host response.
Translational & Preclinical Research
- Scientific Value: Models microcephaly-associated phenotypes including organoid size reduction and cellular debris accumulation post-infection.
- Operational Value: Supports longitudinal assessment of infection outcomes from early exposure to later developmental stages.
- Strategic Value: Improves predictive confidence in preclinical models by recapitulating human-specific cortical layering and gliogenesis timing.
Pipeline & Workflow Integration
The cerebral organoid model fits within the discovery continuum from target validation through lead identification to preclinical assessment of neurotropic compounds.
- Discovery Biology: Enables hypothesis testing of which cells are infectable and which proteins mediate viral entry and pathogenesis.
- Screening: Supports assay readiness through standardized organoid generation, maintenance, and infection protocols in ultra-low attachment plates.
- Analytics: Generates quantitative readouts including organoid size, cell death markers, and viral antigen expression for comparative condition analysis.
- Translational Research: Connects early infection events to downstream phenotypes like disrupted cortical structure and gliogenesis, supporting biomarker-aligned evaluation.
- Enterprise Reuse: Establishes a reusable platform for studying other neurotropic viruses or genetic modifiers of viral susceptibility.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through direct observation of virus-host interactions in a human-relevant system.
- Operational Value: Standardized differentiation and infection workflows reduce variability and support cross-experiment reproducibility.
- Strategic Value: Informs go/no-go decisions by providing early insight into neurological liability of viral pathogens or therapeutic candidates.
- Portfolio Impact: Enables risk-adjusted prioritization of antiviral compounds based on efficacy in preventing organoid dysplasia and cell loss.
Implementation Considerations
- Requires expertise in stem cell culture, organoid generation, and virology under biosafety-level appropriate conditions.
- Dependent on ultra-low attachment plates, enzymatic dissociation tools, and controlled incubation systems for organoid formation.
- Necessitates standardization of media changes, rock inhibitor use, and neural induction timing across batches.
- Adaptation to other models may require optimization of infection timing and multiplicity based on differential progenitor susceptibility.
- Practical limitations include organoid variability and the need for careful handling to avoid mechanical disruption during medium exchange.
Biopharma FAQs
Why does measuring infected neural progenitor cells matter for target validation?
Quantifying Zika virus infection in neural progenitor cells identifies the primary cellular target, supporting mechanistic understanding of viral tropism. This measurement enables hypothesis testing of which cell populations drive pathogenesis in the developing brain. It provides a basis for evaluating therapeutic interventions that aim to block infection in this specific population.
How does isolating the independent variable of viral exposure improve discovery pipeline decisions?
Controlled exposure to Zika virus at defined multiplicities allows researchers to attribute phenotypic changes directly to viral infection. This isolation supports causal inference in target validation and mechanism of action studies. It enables reproducible comparison between infected and mock conditions across experimental replicates.
What quantitative dependent variable measurements enable assessment of infection outcomes?
Organoid size reduction, cellular debris accumulation, and marker expression changes (e.g., phospho-vimentin, MAP2) serve as quantifiable readouts of infection severity. These measurements track disease-relevant phenotypes over time following viral exposure. They support dose-response analysis and screening of compounds that mitigate cytopathic effects.
Why do replication requirements matter for cross-functional collaboration in virology projects?
Regular medium changes and standardized organoid culture ensure consistent developmental stages before infection, reducing variability between replicates. Reproducible organoid formation and infection protocols allow virology, biology, and screening teams to align on experimental expectations. This consistency supports reliable data sharing and joint interpretation of antiviral efficacy.
What statistical analysis capabilities are required before implementing this model in screening campaigns?
The ability to compare organoid size, viability, and marker expression between infected and control groups using t-tests or ANOVA is essential. These analyses determine whether observed differences are statistically significant and reproducible. Such capabilities are needed to validate screening hits and support go/no-go decisions in lead identification.
Chapters in this video
0:05
Title
0:43
Creating Cerebral Organoids from iPSC / hESC 2D Culture (Day 0)
3:30
Cerebral Organoid Maintenance (Day 2)
4:37
Cerebral Organoid Maintenance (Day 3)
5:14
Cerebral Organoid Maintenance (Day 4+)
6:13
Organoid Infection with ZIKV (~Day 24)
7:45
Results: Characterization of ZIKB-infected Organic Degradation
8:47
Conclusion
